Astellas Aims for Global Oncology Position through OSI

By PharmaDeals Analyst

Pharma Deals Review: Vol 2010 Issue 3 (Table of Contents)

Published: 31 Mar-2010

DOI: 10.3833/pdr.v2010.i3.1323     ISSN: 1756-7874

Section: Mergers & Acquisitions

Fulltext:

Abstract

Astellas Pharma made a second attempt to enter the US market to build a world class oncology platform making a tender offer to acquire shares of New York-based OSI Pharmaceuticals for USD 52 per share in cash, amounting to USD 3...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details